A part 1 trial evaluating SENTI-202 demonstrated optimistic preliminary leads to treating relapsed/refractory acute myeloid leukemia.
Constructive preliminary information from a part 1 scientific trial was not too long ago introduced evaluating SENTI-202 for the therapy of relapsed/refractory hematologic malignancies together with acute myeloid leukemia (AML), in response to a information launch from Senti Biosciences.
SENTI-202 a first-in-class, off-the-shelf investigational cell remedy that makes use of engineered pure killer cells to focus on CD33 or FLT3 however not EMCN (CAR-NK), serving to it extra exactly assault sure blood cancers.
Information was offered on April 27 throughout a Scientific Trials Oral Minisymposium on the American Affiliation for Most cancers Analysis (AACR) Annual Assembly 2025.
“Senti was based on engineering Logic Gated cell therapies with the improved means to selectively kill most cancers cells and shield wholesome cells for most cancers indications not addressable by present medication,” Dr. Timothy Lu, co-founder and CEO of Senti Biosciences, stated within the information launch. “Constructing upon these thrilling outcomes, we’re persevering with to prioritize growth of our Logic Gating packages, together with SENTI-202 and extra discovery efforts for stable tumors.”
Trial Efficacy and Security
Two of three sufferers within the preliminary really useful part 2 dose (RP2D) cohort achieved a composite full remission. Amongst seven sufferers evaluable for finest total response, 5 achieved an total response, together with 4 who reached composite full remission — three with full hematologic restoration and one with partial hematologic restoration.
All 4 sufferers who achieved composite full remission had been measurable residual illness damaging by native normal of care. All sufferers who achieved composite full remission stay in remission, with the longest follow-up exceeding eight months, and three sufferers went on to obtain a bone marrow transplant after therapy with SENTI-202.
“Whereas preliminary, the outcomes demonstrated by SENTI-202 up to now proceed to be encouraging,” stated Dr. Stephen A. Strickland, Jr., director, Leukemia Analysis for Sarah Cannon Analysis Institute, and the lead writer for the AACR summary, within the information launch.
He continued, “There stays a major unmet medical want in AML for remedies that may overcome tumor heterogeneity and spare wholesome cells. Early outcomes are encouraging, not just for the deep sturdy full remissions, but additionally for the wonderful security profile famous so far. I sit up for seeing extra information and exploring the potential of SENTI-202 to supply a much-needed therapy choice to folks residing with AML.”
Relating to security, SENTI-202 was usually properly tolerated, with uncomfortable side effects in step with different investigational pure killer cell therapies and sufferers with AML receiving lymphodepleting chemotherapy. Amongst grade 3 (extreme) or greater uncomfortable side effects seen in multiple affected person, 4 sufferers every skilled febrile neutropenia and low platelet rely, and two sufferers every had anemia and stomach ache. All however one among these results had been thought of unrelated to SENTI-202 or attributed to lymphodepleting chemotherapy. No grade 5 (demise) uncomfortable side effects occurred.
Continuation of Trial and Presentation of Information
The part 1 research of SENTI-202 is continuous to enroll sufferers to verify the preliminary really useful part 2 dose, adopted by disease-specific growth cohorts.
“Primarily based on our scientific, correlative and preclinical information, we imagine SENTI-202 has the potential to supply a secure and efficient therapy choice for AML,” Dr. Kanya Rajangam, president, head of R&D and chief medical officer of Senti Bio, stated within the information launch. “We stay centered on the profitable execution of the research and sit up for additional exploring SENTI-202’s potential.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
